NEW YORK (GenomeWeb News) – Pressure BioSciences has closed the sale of $1.16 million of units in the first tranche of its $2.5 million private placement.

Each unit was priced at $18.80 and consisted of one share of non-voting Series B convertible preferred stock, and one warrant to purchase a share of Series B convertible preferred stock at an exercise price of $23.80 per share, expiring on Aug. 11, 2011.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.